Merck doesn't have to repay La. for Vioxx; Former BMS execs in deal with prosecutors;

 @FiercePharma: Journal questions independence of key Crestor trial. Article  | Follow @FiercePharma

> Merck won the first trial over withdrawn painkiller Vioxx brought by a state trying to recoup what it paid for the former blockbuster drug. Article

> Two former Bristol-Myers Squibb executives have reached deals with U.S. prosecutors that will end their criminal fraud cases as long as they stay out of trouble. Report

> Drugmakers including King Pharmaceuticals and Johnson & Johnson won't need to register doctors or patients as part of a plan to minimize the risks of long-acting painkillers, U.S. regulators said. Report

> Soleil Securities initiated coverage on shares of Eli Lilly with a sell rating, noting that several products are set to lose their patent protection; Soleil set a price target of $28 per share. Story

> India's oldest pharmaceutical company, Alembic Ltd, is spinning off its main pharmaceutical business into a separate subsidiary company, Alembic Pharma (APL), to unlock the value of its branded formulation business. Article

Biotech News

@FierceBiotech: Bind banks $12.4M round as lead program heads into PhI. Article  | Follow @FierceBiotech

@JohnCFierce: Three doses of a Forest pain drug can't significantly outperform a placebo in Ph2 diabetes study. Article  | @JohnCFierce

> On a spree, Sanofi scoops up TargeGen in $635 million deal. Story

> Noxxon's Morich to leave in August. Item

> Calistoga banks $40 million Series C for pivotal trial work. Report

> SV Life Sciences flush with venture cash, bullish on exit deals. News

Drug Delivery News

> Start-up gains funds to test tumor-targeting tech. Item

> OctoPlus strikes delivery tech development pact with Novartis. Story

> Sosei lands deal for new nanotech platform technology. Report

> UK researchers fine tune nanogel delivery system. Article

Biomarkers News

> Survey: Use of biomarkers growing fast among drug developers. News

> CDI, Promega to collaborate on in vitro assays. Report

> Febit chops staff as it focuses on microRNA biomarker discovery. Item

Medical Device News

> Study: Medtronic insulin pump bests injections. Story

> Council mulls improvements to med device development. Report

> U of M fellows look to change how IVs are used. Item

Special Report: Top top 10 pharma cargo thefts of 2009/2010. Special Report

And Finally... Intensive control of blood sugar doesn't reduce the odds of cardiovascular disease for those with long-term type 2 diabetes who are at risk of heart problems, but it may have some other benefits, a new analysis suggests. Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.